Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-targeting CAR T Cells for Refractory B Cell Lymphoma
NCT02547948Phase 2Withdrawn
- Sponsor
- Fuda Cancer Hospital
- Start
- Sep 2015
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
Phase 2, open-label trial in B cell lymphoma (2 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: CAR T cell persistence at 24 months. Planned start Sep 2015; status: withdrawn.
02
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02547948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547948.